Featured this month

The Microscopic Crisis: The Antibiotic Resistance Crisis

Antibiotics have been among the most important medical advances of the twentieth century, transforming once-lethal bacterial infections into treatable conditions and supporting modern medical practices such as surgery, chemotherapy, and organ transplantation. However, the widespread use of antibiotics has also led to a growing global challenge: antibiotic resistance. As bacteria adapt to survive antibiotic exposure, many treatments that were once effective are becoming less reliable, resulting in increased treatment failure and mortality¹. Antibiotic resistance is now recognized as a major global public health concern. The misuse and overuse of antibiotics in healthcare settings and agriculture have accelerated the emergence of resistant bacterial strains. In 2019, antimicrobial-resistant infections were associated with approximately 4.95 million deaths worldwide, with an estimated 1.27 million deaths directly attributable to antibiotic resistance². These infections particularly affect hospitalized and immunocompromised patients, often leading to longer hospital stays, higher healthcare costs, and increased risk of death³. Epidemiological studies also show that resistant infections are rising in both high- and low-income countries, emphasizing the global nature of this problem⁴. Antibiotic resistance refers to the ability of bacteria to survive and grow in the presence of antibiotics that would normally inhibit or kill them⁵. As resistance increases, standard treatments become less effective, allowing infections to persist and spread more easily, especially within healthcare environments. At the same time, the development of new antibiotics has slowed, making it difficult to keep pace with the rapid evolution of resistant bacteria. One group of bacteria that plays a major role in this crisis is the ESKAPE pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. These pathogens are responsible for a large proportion of hospital-acquired infections and are particularly concerning due to their resistance to multiple classes of antibiotics⁶. As a result, ESKAPE pathogens have become a key focus of research and public health efforts. Understanding the scope of the antibiotic resistance crisis and the role of ESKAPE pathogens is essential for developing effective strategies to address this growing threat. The following sections will examine the mechanisms underlying antibiotic resistance, its transmission, and current therapeutic approaches. There are different ways that pathogens resist antibiotics. One method uses enzymes to inactivate or degrade the antibiotic. The pathogen produces specific enzymes that chemically alter or physically destroy the antibiotic before it can reach its target. Its mechanisms include hydrolysis, where bacteria secrete enzymes like beta-lactamases that break the chemical bonds of the antibiotic (such as the beta-lactam ring in penicillins)⁷, rendering it inactive. Pathogens can also produce enzymes that add chemical groups, such as phosphate, acetyl, or adenyl groups, to the antibiotic. These modifications change the shape or charge of the drug, preventing it from binding to its intended bacterial target. In addition to modifying the antibiotic, pathogens can evolve to change the structure of the molecule that the antibiotic is designed to attack, making the drug "blind" to its target. Spontaneous mutations in bacterial DNA can alter the amino acid sequence of target proteins, such as DNA gyrase (targeted by quinolones) or RNA polymerase (targeted by rifampin)⁸. Besides genetically modifying the target molecule, it is possible to physically cover its shape. Some bacteria produce "protector" proteins that physically shield the target site, or they use enzymes to add a methyl group to a target, which prevents the drug from attaching without disrupting the cell's normal function. Furthermore, pathogens can prevent antibiotics from entering the cell by reinforcing their outer defenses, a strategy particularly common in Gram-negative bacteria⁹. Bacteria can reduce the number of porins (protein channels) in their outer membrane or change their selectivity to block the entry of hydrophilic drugs like carbapenems. To further decrease permeability, pathogens form biofilms, which are communities encased in a sticky extracellular matrix that acts as a physical barrier, slowing down the penetration of antibiotics. Also, changing the composition of the bacterial cell membrane makes it more difficult for lipophilic antibiotics to diffuse into the cell. Lastly, even if an antibiotic successfully enters the cell, pathogens can use specialized "pumps" to immediately eject the drug. Bacteria utilize efflux pumps, which are complex proteins embedded in the cell membrane, to actively transport antibiotics out of the cytoplasm¹⁰. These pumps typically use energy from ATP or the proton motive force to move drugs against a concentration gradient. Many efflux pumps are "promiscuous," meaning they can recognize and expel many different classes of antibiotics, leading to resistance to multiple drugs simultaneously Bacteria acquire antibiotic resistance through two fundamental pathways: vertical gene transfer (VGT) via spontaneous mutation and horizontal gene transfer (HGT) through mechanisms that enable genetic exchange between cells¹³. While vertical transfer occurs through normal cell division where mutations are passed to daughter cells, horizontal gene transfer plays an important role in bacterial evolution and poses a more significant threat due to its capacity to rapidly spread resistance genes¹⁴. Horizontal gene transfer occurs through three primary mechanisms: transformation, transduction, and conjugation. Transformation involves the uptake of extracellular DNA fragments from the environment by competent bacterial cells¹⁴. When bacteria die and lyse, their chromosomal and plasmid DNA is released into the surrounding medium. Living bacteria with specialized uptake machinery can recognize, bind, and integrate it into their own genetic material and gain antibiotic resistance. Transduction represents genetic transfer mediated by bacteriophages, viruses that infect bacteria and transfer DNA between bacterial cells. During viral replication, packaging errors result in bacterial DNA being incorporated into phage particles instead of viral genetic material. When these phages infect new bacterial hosts, they inject the bacterial DNA into recipient cells. In generalized transduction, random pieces of bacterial DNA are transferred during the lytic cycle, while specialized transduction moves specific genes that are located near the phage insertion site¹⁵. Conjugation is the most efficient and clinically significant mechanism of horizontal gene transfer, requiring direct physical contact between donor and recipient bacterial cells through a specialized structure known as a pilus. During conjugation, the donor cell replicates its plasmid while simultaneously transferring a copy into the recipient cell through the pilus, resulting in both cells carrying the resistance plasmid¹⁵. This process enables the rapid dissemination of antibiotic resistance genes within and between bacterial species. Conjugative plasmids frequently carry multiple resistance genes simultaneously, enabling single-step acquisition of multidrug resistance across even distantly related species¹⁶. Mobile genetic elements (MGE) further facilitate antibiotic resistance spread in bacteria. Transposons are DNA segments that can move between chromosomes and plasmids, carrying resistance genes with them. Integrons serve as gene collection systems that can capture and store multiple resistance gene cassettes in a single structure¹⁷. Together, these elements allow bacteria to build and rearrange combinations of resistance genes as needed, helping them quickly adapt to antibiotic exposure and survive in changing environments. The ESKAPE pathogens identifies six multidrug resistant (MDR) bacteria: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. They have adapted to the modern health-care environment and continue to cause infections despite the development of antibiotics and antibiotic adjuvants such as novel β-lactamase inhibitors combined with β-lactam antibiotics that prevent bacteria from inactivating the antibiotic¹⁸. However, they continue to challenge therapeutic outcomes globally. ESKAPE pathogens are commonly associated with several life-threatening hospital acquired infections such as bloodstream infections, pneumonia, meningitis, urinary tract infections (UTI), and wound infections¹⁹. The mechanisms behind MDR in ESKAPE pathogens are sophisticated and multifaceted, with multidrug efflux pumps and biofilm formation represent significant contributors of antimicrobial resistance mechanisms. Multidrug efflux pumps are inner membrane transporters that export antibiotics out of bacterial cells before they can reach lethal intracellular concentrations²⁰. They can be further classified by energy coupling and their structure into six different families: ABC (ATP-binding cassette), MF (major facilitator), RND (resistance-nodulation-division), MATE (multidrug and toxic compound extrusion), SMR (small multidrug resistance), and the relatively new family, PACE (proteobacterial antimicrobial compound efflux)²¹. With the use of these pumps, bacteria can recognize diverse antibiotics as well as β-lactam, contributing to broad-spectrum resistance. These pumps recognize molecular structures of antibiotics that come into bacteria and prevent before the target locations are reached and actively exported. Gene expression of multidrug efflux pump has increased in many resistant bacteria and contributes to both intrinsic and acquired resistance²⁰. Biofilm formation is a major resistance strategy used by ESKAPE pathogens to survive from antibiotic treatments. Biofilms are organized bacterial communities that develop through a series of stages, starting with the attachment of free-living bacteria to a surface, followed by irreversible adhesion and maturation that develops into complex three-dimensional structures, and dispersion to colonize new sites²². As the biofilm matures, bacteria produce an extracellular polymeric substance (EPS) matrix made up of polysaccharides, proteins, lipids, and extracellular DNA that surrounds and protects the community²². This EPS matrix acts as a barrier that limits antibiotic penetration due to increased thickness, decreased diffusion efficacy and concentration of antibiotics. In addition to restricting drug diffusion, biofilms create diverse internal environments by low oxygen levels, limited nutrient availability, and mechanical pressure. These conditions are favorable habitat for various types of biofilms. Thus, slowing bacterial growth and metabolism, decreasing the effectiveness of antibiotics²². Biofilms also contain persister cells, which are dormant, highly tolerant variants that survive antibiotic treatment and reactivate and regenerate the biofilm after the treatment is discontinued, leading to persistent and recurring infections²³. In conclusion, antibiotic resistance represents a rapidly escalating global health crisis driven by the overuse and misuse of antibiotics and the remarkable adaptability of bacteria. As outlined in this report, pathogens have evolved diverse and sophisticated mechanisms—including enzymatic drug inactivation, target modification, reduced permeability, and active efflux—to evade antimicrobial treatments. The problem is further amplified by the efficient transmission of resistance genes, particularly through horizontal gene transfer, enabling rapid spread across bacterial populations. ESKAPE pathogens exemplify the severity of this issue, as their multidrug resistance, biofilm formation, and persistence mechanisms continue to undermine current therapeutic strategies and contribute to life-threatening infections in healthcare settings. Addressing this crisis requires a multifaceted approach that includes improved antibiotic stewardship, continued research into novel therapeutics, and a deeper understanding of resistance mechanisms and transmission pathways. Without coordinated global efforts, the effectiveness of antibiotics will continue to decline, threatening the foundation of modern medicine and increasing the risk of entering a post-antibiotic era. 1. World Health Organization. Antimicrobial resistance. Geneva (CH): WHO; 2023. 2. Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. 3. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309–318. 4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Atlanta (GA): CDC; 2019. 5. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2). 6. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079–1081. 7. (Antibiotic Resistance Mechanism) Egorov AM, Ulyashova MM, Rubtsova MYu. 2018. Bacterial Enzymes and Antibiotic Resistance. Acta Naturae. 10(4):33–48. doi:https://doi.org/10.32607/20758251-2018-10-4-33-48. 8. (Antibiotic Resistance Mechanism) ‌Halawa EM, Fadel M, Al-Rabia MW, Behairy A, Nouh NA, Abdo M, Olga R, Fericean L, Atwa AM, El-Nablaway M, et al. 2023. Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance. Frontiers in Pharmacology. 14(1):1305294. doi:https://doi.org/10.3389/fphar.2023.1305294. 9. ‌(Antibiotic Resistance Mechanism) Ghai I, Ghai S. 2018. Understanding antibiotic resistance via outer membrane permeability. Infection and Drug Resistance. Volume 11:523–530. doi:https://doi.org/10.2147/idr.s156995. 10. (Antibiotic Resistance Mechanism) ‌Sinha S, Aggarwal S, Singh DV. 2024. Efflux pumps: gatekeepers of antibiotic resistance in Staphylococcus aureus biofilms. Microbial Cell. 11:368–377. doi:https://doi.org/10.15698/mic2024.11.839. https://pmc.ncbi.nlm.nih.gov/articles/PMC11576857/. 11. (Antibiotic Resistance Mechanism, Figure 1) Wright GD. 2010. Q&A: Antibiotic resistance: where does it come from and what can we do about it? BMC Biology. 8(1). doi:https://doi.org/10.1186/1741-7007-8-123. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2942819/. 12. (Antibiotic Resistance Mechanism, Figure 2) ‌Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes (IF=3.533) - Scientific Figure on ResearchGate. Available from: https://www.researchgate.net/figure/Fig-1-Common-Antibiotic-Drug-Resistance-Mechanisms-adopted-by-different-bacterial-and_fig1_348044688 [accessed 17 Jan 2026] 13. Tao S, Chen H, Li N, Wang T, Liang W. 2022. The spread of antibiotic resistance genes in vivo model. Can J Infect Dis Med Microbiol. 2022:3348695. doi:10.1155/2022/3348695. 14. Burmeister AR. 2015. Horizontal gene transfer. Evol Med Public Health. 2015(1):193–194. doi:10.1093/emph/eov018. 15. Brown JR. Bacteriophage transduction in bacteria. In: Antibiotic Resistance Genes: Methods and Protocols. Totowa (NJ): Humana Press; 2015. p. 145–158. NCBI Bookshelf: NBK493185. 16. Goldlust K, Ducret A, Halte M, Dedieu-Berne A, Erhardt M, Lesterlin C. 2023. The F pilus serves as a conduit for the DNA during conjugation between physically distant bacteria. Proc Natl Acad Sci U S A. 120(47):e2310842120. doi:10.1073/pnas.2310842120. 17. Mahillon J, Chandler M. Insertion sequences. In: Molecular Genetics of Bacteria. Washington (DC): ASM Press; 2004. p. 307–364. NCBI Bookshelf: NBK216503. 18. Ghaly TM, Rajabal V, Penesyan A, Coleman NV, Paulsen IT, Gillings MR, Tetu SG. 2023. Functional enrichment of integrons: facilitators of antimicrobial resistance and niche adaptation. iScience. 26(11):108301. doi:10.1016/j.isci.2023.108301. 19. Miller WR, Arias CA. 2024. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nat Rev Microbiol. 22:598–616. 20. Denissen J, Reyneke B, Waso-Reyneke M, Havenga B, Barnard T, Khan S, Khan W. 2022. Prevalence of ESKAPE pathogens in the environment: antibiotic resistance status, community-acquired infection and risk to human health. Int J Hyg Environ Health. 245:114006. 21. Nishino K, Yamasaki S, Nakashima R, Zwama M, Hayashi-Nishino M. 2021. Function and inhibitory mechanisms of multidrug efflux pumps. Front Microbiol. 12:737288. doi:10.3389/fmicb.2021.737288. 22. Hassan KA, Liu Q, Henderson PJF, Paulsen IT. 2015. Homologs of the Acinetobacter baumannii AceI transporter represent a new family of bacterial multidrug efflux systems. mBio. 6(1):e01982-14. doi:10.1128/mBio.01982-14. 23. Grooters KE, Ku JC, Richter DM, Krinock MJ, Minor A, Li P, Kim A, Sawyer R, Li Y. 2024. Strategies for combating antibiotic resistance in bacterial biofilms. Front Cell Infect Microbiol. 14:1352273. doi:10.3389/fcimb.2024.1352273. 24. Sahoo K, Meshram S. 2024. Biofilm formation in chronic infections: a comprehensive review of pathogenesis, clinical implications, and novel therapeutic approaches. Cureus. 16(10):e70629. doi:10.7759/cureus.70629.

Sponsor

Hallasan

Hallasan is a premium soju from Jeju Island, South Korea, made using naturally alkaline, volcanic rock-filtered water, which gives it a clean and crisp taste. The original version is known for a higher alcohol content 21% and smooth profile, while flavored varieties, such as Mandarin and Lychee, are made with natural fruit juice for a balanced sweetness. It's often served cold and is versatile for sipping or mixing in cocktails.